Correa DD, Hess LM. Cognitive function and quality of life in ovarian cancer. Gynecol Oncol. 2012;124(3):404–9.
Hess LM, Insel KC. Chemotherapy-related change in cognitive function: a conceptual model. Oncol Nurs Forum. 2007;34(5):981–94.
Hodgson KD, et al. A meta-analysis of the effects of chemotherapy on cognition in patients with cancer. Cancer Treat Rev. 2013;39(3):297–304.
Lange M, et al. Baseline cognitive functions among elderly patients with localised breast cancer. Eur J Cancer. 2014;50(13):2181–9.
Merriman JD, et al. Proposed mechanisms for cancer- and treatment-related cognitive changes. Semin Oncol Nurs. 2013;29(4):260–9.
van Amstel PFK. Distress screening remains important during follow-up after primary breast cancer treatment. Support Care Cancer. 2013;21(8):2107–15.
Janelsins MC, et al. Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry. 2014;26(1):102–13.
Silberfarb PM. Chemotherapy and cognitive defects in cancer patients. Annu Rev Med. 1983;34:35–46.
Cull A, et al. Neurological and cognitive impairment in long-term survivors of small cell lung cancer. Eur J Cancer. 1994;30A(8):1067–74.
Lindner OC, et al. A meta-analysis of cognitive impairment following adult cancer chemotherapy. Neuropsychology. 2014;28(5):726–40.
Vardy J, et al. Assessing cognitive function in cancer patients. Support Care Cancer. 2006;14(11):1111–8.
Craig CD, et al. Cognitive impairment in gynecologic cancers: a systematic review of current approaches to diagnosis and treatment. Support Care Cancer. 2014;22(1):279–87.
Erlanger DM, et al. Development and validation of a web-based screening tool for monitoring cognitive status. J Head Trauma Rehabil. 2002;17(5):458–76.
Collie A, Darby D, Maruff P. Computerised cognitive assessment of athletes with sports related head injury. Br J Sports Med. 2001;35(5):297–302.
Fogel BS. The high sensitivity cognitive screen. Int Psychogeriatr. 1991;3(2):273–88.
Randolph C, et al. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 1998;20(3):310–9.
Cheung YT, Chan A. Linguistic validation of Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog): methodological concerns. Support Care Cancer. 2013;21(3):655–6.
Jansen CE, et al. A meta-analysis of the sensitivity of various neuropsychological tests used to detect chemotherapy-induced cognitive impairment in patients with breast cancer. Oncol Nurs Forum. 2007;34(5):997–1005.
Meyers CA, Wefel JS. The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol. 2003;21(19):3557–8.
Wefel JS, et al. International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 2011;12(7):703–8.
Shapiro AM, et al. Construct and concurrent validity of the Hopkins verbal learning test-revised. Clin Neuropsychol. 1999;13(3):348–58.
Gondi V, et al. Decline in tested and self-reported cognitive functioning after prophylactic cranial irradiation for lung cancer: pooled secondary analysis of radiation therapy oncology group randomized trials 0212 and 0214. Int J Radiat Oncol Biol Phys. 2013;86(4):656–64.
Fan HG, et al. The influence of erythropoietin on cognitive function in women following chemotherapy for breast cancer. Psychooncology. 2009;18(2):156–61.
Johnson DR, et al. Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma. Neuro Oncol. 2012;14(6):808–16.
Reitan RM. Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills. 1958;8:271–6.
Green J. Neuropsychological evaluation of the older adult. San Diego: Academic; 2000.
Cruzado JA, et al. Longitudinal study of cognitive dysfunctions induced by adjuvant chemotherapy in colon cancer patients. Support Care Cancer. 2014;22(7):1815–23.
Tchen N, et al. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol. 2003;21(22):4175–83.
Hermelink K, et al. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer. 2007;109(9):1905–13.
Wefel JS, et al. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer. 2004;100(11):2292–9.
Hensley ML, et al. Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning. Gynecol Oncol. 2006;102(2):270–7.
Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2005;104(4):788–93.
Strauss E, Sherman E, Spreen O. A compendium of neuropsychological tests: administration, norms and commentary. Oxford: Oxford University Press; 2006.
Ruff RM, et al. Benton controlled oral word association test: reliability and updated norms. Arch Clin Neuropsychol. 1996;11(4):329–38.
Scheibel RS, Meyers CA, Levin VA. Cognitive dysfunction following surgery for intracerebral glioma: influence of histopathology, lesion location, and treatment. J Neurooncol. 1996;30(1):61–9.
Jim HS, et al. Cognitive functioning in breast cancer survivors: a controlled comparison. Cancer. 2009;115(8):1776–83.
Wefel JS, et al. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 2010;116(14):3348–56.
Fayers P, Bottomley A. Quality of life research within the EORTC-the EORTC QLQ-C30. European organisation for research and treatment of cancer. Eur J Cancer. 2002;38 Suppl 4:S125–33.
Smith AB, et al. Most domains of the european organisation for research and treatment of cancer quality of life questionnaire C30 are reliable. J Clin Epidemiol. 2014;67(8):952–7.
Wagner LI, Sweet J, Butt Z, Lai J, Cella D. Measuring patient self-reported cognitive function: development of the functional assessment of cancer therapy-cognitive function instrument. J Support Oncol. 2009;7:32–9.
Joly F, et al. French version of the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) version 3. Support Care Cancer. 2012;20(12):3297–305.
Jim HS, et al. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol. 2012;30(29):3578–87.
Lepage C, et al. A prospective study of grey matter and cognitive function alterations in chemotherapy-treated breast cancer patients. Springerplus. 2014;3:444.
McDonald BC, et al. Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res Treat. 2010;123(3):819–28.
Bergouignan L, et al. Breast cancer affects both the hippocampus volume and the episodic autobiographical memory retrieval. PLoS One. 2011;6(10):e25349.
McDonald BC, et al. Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study. Brain Behav Immun. 2013;30(Suppl):S117–25.
Conroy SK, et al. Alterations in brain structure and function in breast cancer survivors: effect of post-chemotherapy interval and relation to oxidative DNA damage. Breast Cancer Res Treat. 2013;137(2):493–502.
Koppelmans V, et al. Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy. Breast Cancer Res Treat. 2012;132(3):1099–106.
de Ruiter MB, et al. Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging. Hum Brain Mapp. 2012;33(12):2971–83.
Stouten-Kemperman MM, et al. Neurotoxicity in breast cancer survivors >/=10 years post-treatment is dependent on treatment type. Brain Imaging Behav. 2014;9(2):275–84.
Inagaki M, et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer. 2007;109(1):146–56.
Deprez S, et al. Longitudinal assessment of chemotherapy-induced alterations in brain activation during multitasking and its relation with cognitive complaints. J Clin Oncol. 2014;32(19):2031–8.
McDonald BC, et al. Alterations in brain activation during working memory processing associated with breast cancer and treatment: a prospective functional magnetic resonance imaging study. J Clin Oncol. 2012;30(20):2500–8.
Koppelmans V, et al. Global and focal white matter integrity in breast cancer survivors 20 years after adjuvant chemotherapy. Hum Brain Mapp. 2014;35(3):889–99.
Abraham J, et al. Adjuvant chemotherapy for breast cancer: effects on cerebral white matter seen in diffusion tensor imaging. Clin Breast Cancer. 2008;8(1):88–91.
Deprez S, et al. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol. 2012;30(3):274–81.
Deprez S, et al. Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. Hum Brain Mapp. 2011;32(3):480–93.
Kesler SR, Kent JS, O'Hara R. Prefrontal cortex and executive function impairments in primary breast cancer. Arch Neurol. 2011;68(11):1447–53.
de Ruiter MB, et al. Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp. 2011;32(8):1206–19.
Silverman DH, et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy. Breast Cancer Res Treat. 2007;103(3):303–11.
Ferguson RJ, et al. Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol. 2007;25(25):3866–70.
Scherling C, et al. Prechemotherapy differences in response inhibition in breast cancer patients compared to controls: a functional magnetic resonance imaging study. J Clin Exp Neuropsychol. 2012;34(5):543–60.
Bruno J, Hosseini SM, Kesler S. Altered resting state functional brain network topology in chemotherapy-treated breast cancer survivors. Neurobiol Dis. 2012;48(3):329–38.
Cimprich B, et al. Prechemotherapy alterations in brain function in women with breast cancer. J Clin Exp Neuropsychol. 2010;32(3):324–31.
Askren MK, et al. Neuromarkers of fatigue and cognitive complaints following chemotherapy for breast cancer: a prospective fMRI investigation. Breast Cancer Res Treat. 2014;147(2):445–55.
Deprez S, et al. Diffusion tensor MRI of chemotherapy-induced cognitive impairment in non-CNS cancer patients: a review. Brain Imaging Behav. 2013;7(4):409–35.
Reuter-Lorenz PA, Cimprich B. Cognitive function and breast cancer: promise and potential insights from functional brain imaging. Breast Cancer Res Treat. 2013;137(1):33–43.
Kaiser J, Bledowski C, Dietrich J. Neural correlates of chemotherapy-related cognitive impairment. Cortex. 2014;54:33–50.
Hess LM, Huang H, Hanlon A, Robinson W, Johnson R, Chambers SK, Mannel RS, Puls L, Davidson SA, Method M, Lele S, Havrilesky L, Nelson T, Alberts DS.Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: An NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2015 Oct 8. pii: S0090-8258(15)30152-9. doi: 10.1016/j.ygyno.2015.10.003.
Using bio markers to predict disease recurrence and cognitive function in high risk breast cancer (Cyto-Cog). 2012. 10 Oct 2014; Available from: http://www.clinicaltrials.gov/ct2/show/NCT00756132.
Effects of meditation on cognitive function and quality of life. 2014. 10 Oct 2014; Available from: http://www.clinicaltrials.gov/ct2/show/NCT02162329.
The effects of physical activity and low-dose ibuprofen on cognitive function in cancer patients. 2014. 10 Oct 2014; Available from: http://www.clinicaltrials.gov/ct2/show/NCT01238120.
Von Ah D, Allen DH, Jansen CE, Wulff J, Johnson L, Irwin MM, Maloney CM, Moriarty KA, Vrabel M. Putting evidence into practice®: evidence-based interventions for cancer and cancer treatment-related cognitive impairment. 2014 10 Oct 2014; Available from: https://www.ons.org/practice-resources/pep/cognitive-impairment.
Von Ah D, Jansen C, Allen DH, Schiavone RM, Wulff J. Putting evidence into practice: evidence-based interventions for cancer and cancer treatment-related cognitive function. Clin J Oncol Nurs. 2011;15(6):607–15.
Hassler MR, et al. Neurocognitive training in patients with high-grade glioma: a pilot study. J Neurooncol. 2010;97(1):109–15.
Poppelreuter M, Weis J, Bartsch HH. Effects of specific neuropsychological training programs for breast cancer patients after adjuvant chemotherapy. J Psychosoc Oncol. 2009;27(2):274–96.
Von Ah D, et al. Advanced cognitive training for breast cancer survivors: a randomized controlled trial. Breast Cancer Res Treat. 2012;135(3):799–809.
Cognitive rehabilitation group intervention for breast cancer survivors. 2014. 20 Oct 14; Available from: http://clinicaltrials.gov/ct2/show/NCT01540955.
LIVESTRONG Care Plan. 2014. 24 Oct 2014; Available from: http://www.livestrongcareplan.org/.
Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy (CANTAB). 2014. 10 Oct 14; Available from: http://www.clinicaltrials.gov/ct2/show/NCT01382082.
The impact of androgen ablation therapy on cognitive functioning and functional status in men with prostate cancer age 65 and older. 2014. 10 Oct 14; Available from: http://www.clinicaltrials.gov/ct2/show/nct00579072.
Cancer and disorders of cognitive functions and quality of life: “cognitive rehabilitation in patients suffering from cancer and treated with chemotherapy”. 2014. 10 Oct 2014; Available from: http://www.clinicaltrials.gov/ct2/show/NCT01788618.
Costas-Muniz R, et al. Cancer stage knowledge and desire for information: mismatch in Latino cancer patients? J Cancer Educ. 2013;28(3):458–65.
Qiu WL, et al. Requests for health education from Chinese cancer patients during their recovery period: a cross-sectional study. J Cancer Educ. 2013;28(3):428–34.
Oral therapies in oncology: cognitive function and compliance. 2014 10 Oct 2014; Available from: http://www.clinicaltrials.gov/ct2/show/NCT01597284.
Dale J, et al. Tightening up? Impact of musculoskeletal ultrasound disease activity assessment on early rheumatoid arthritis patients treated using a treat to target strategy. Arthritis Care Res. 2014;66(1):19–26.
Memory and thinking skills workshop in improving cognitive rehabilitation in gynecologic and breast cancer survivors. 2014. 10 Oct 2014; Available from: http://www.clinicaltrials.gov/ct2/show/NCT01641068.
Masucci L, et al. Predictors of health service use over the palliative care trajectory. J Palliat Med. 2013;16(5):524–30.